Physician

Jonathan Vernon Amos, M.D.

According to 2025 Medicare claims, Jonathan Amos, M.D. (NPI: 1740660604) practices rheumatology in the Kansas City, MO-KS market, with the plurality of this provider's patient population coming from Johnson, KS. This provider's primary affiliated billing organization is MID-AMERICA RHEUMATOLOGY CONSULTANTS (NPI: 1043204852; TIN: 480929053) and primary practice location at 66209-3749.

Amos' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 385 traditional Medicare patients, billed 112,394 HCPCS/CPT codes, and received $1,161,945 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 660 prescription claims across 149 beneficiaries totaling $151,611 in drug costs, led by Hydroxychloroquine Sulfate (Hydroxychloroquine Sulfate). Open Payments data shows 36 records totaling $814. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $343,909 and ending at $1,161,945. Concurrently, Part D prescription costs have risen steadily, from $2,613 to $151,611. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	183	34,169	$343,909
2021	321	69,823	$836,949
2022	427	135,314	$1,340,041
2023	353	81,928	$960,793
2024	385	112,394	$1,161,945

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	36	$2,613
2016	43	175	$3,782
2017	53	236	$11,798
2018	30	186	$11,044
2019	13	33	$8,951
2020	100	337	$246,029
2021	111	584	$28,046
2022	121	558	$25,499
2023	121	482	$35,047
2024	149	660	$151,611

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	58	58	$157
96413	Administration of chemotherapy into vein, 1 hour or less	147	374	$99
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	289	562	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	62	77	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	137	249	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	139	10,868	$9,030
Methotrexate	Methotrexate Sodium	76	5,077	$2,078
Mycophenolate Mofetil	Mycophenolate Mofetil	11	675	$1,693
Prednisone	Prednisone	116	4,784	$1,032
Sulfasalazine	Sulfasalazine	18	1,362	$737

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$814	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jonathan Vernon Amos, M.D.?

Tedicare shows public-source Medicare data for Jonathan Vernon Amos, M.D. (NPI 1740660604), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jonathan Vernon Amos, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jonathan Vernon Amos, M.D.?

Jonathan Vernon Amos, M.D. is linked to MID-AMERICA RHEUMATOLOGY CONSULTANTS (billing NPI 1043204852) in the available physician profile data.

Does Jonathan Vernon Amos, M.D. have Open Payments data?

Jonathan Vernon Amos, M.D. has 36 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.